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JESSE A. GOLDNER* 
On Friday, March 20, 2012, the Saint Louis University Center for Health 
Law Studies and the Journal of Health Law & Policy hosted the 24th annual 
Health Law Symposium entitled Drugs and Money. The genesis of this year’s 
Symposium program, in some respects, is a lengthy one. In 1982, a small 
group of law faculty at Saint Louis University,1 over lunch at the law school’s 
beloved watering hole (Humphrey’s), sketched out on a napkin (actually 
rediscovered a few years ago) the outline for what soon became the School 
of Law’s Center for Health Law Studies. This year has been dedicated to a 
celebration of the Center’s 30th anniversary. Activities included a reception 
for alumni and other friends of the Center attended by over 200 people, 
held at the United States Supreme Court, and a 30th anniversary 
conference, keynoted by Paul Starr, Professor of Sociology and Public Affairs 
and Stuart Professor of Communications and Public Affairs at Princeton 
University. The conference also celebrated the 30th anniversary of Dr. Starr’s 
classic study, The Social Transformation of American Medicine,2 as well as 
the publication of his more recent book Remedy and Reaction: The Peculiar 
American Struggle over Health Care Reform.3 The scholarship arising out of 
that conference will be published in Volume 6, Issue 2 of this Journal. 
The Symposium that served as the basis for the scholarship presented 
here was yet another anniversary year activity and came about largely due 
to a chance discussion during the 2010-2011 academic year between 
 
* John D. Valentine Professor of Law, Professor of Law in Psychiatry and Professor of 
Pediatrics, Saint Louis University, former Director of the School of Law’s Center for Health Law 
Studies. 
 1. Sandra Johnson, now Tenet Professor of Law and Ethics, Emerita at Saint Louis 
University; Michael Wolff, currently Distinguished Professor of Law and Co-Director of the 
Center for the Interdisciplinary Study of Law at Saint Louis University; Nicolas Terry, currently 
Hall Render Professor and Co-Director of the William S. and Christine S. Hall Center for Law 
and Health at Indiana University Indianapolis; and myself. 
 2. PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE (1982). 
 3. PAUL STARR, REMEDY AND REACTION: THE PECULIAR AMERICAN STRUGGLE OVER HEALTH 
CARE REFORM (2011). 
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Professor Thomas (Tim) Greaney4 and Marc Rodwin. The conversation 
included the possibility of devoting a Symposium to the topic of conflicts of 
interest in healthcare — a topic on which, as noted below, Marc is one of 
the country’s leading authorities. As we began to identify suitable principal 
speakers for the program, over time the topic for the Symposium morphed 
somewhat to focus more specifically on issues related to the pharmaceutical 
industry and more broadly on financial issues in general. Hence its apt title. 
Center faculty, and in particular Tim Greaney’s,5 fingerprints can be seen in 
the conceptualization of the program. Also, special thanks are owed to 
Professor Rob Gatter, co-director of the Center, who, in addition to helping 
identify commentators, keeps the rest of us on course. In addition, Amy 
Sanders, Esq., Assistant Director of the Center, and Cheryl Cooper, the 
Center’s Program Coordinator, were responsible for the various logistics 
involved in putting on the Symposium. 
Certainly, this is neither the first nor likely the last Health Law Symposium 
to cover topics related to healthcare financing and/or the pharmaceutical 
industry. Symposium programs that touched on these issues over the last two 
decades include: Implementing Health Reform Fairness, Accountability and 
Competition (2011), Medicare: After the Medicare Modernization Act 
(2007), From Risk to Ruin: Shifting the Cost of Health Care to Consumers 
(2005), Taking the Pulse of Medicaid (2000), Medical Necessity: Fraud, 
False Claims and Managed Care (1998), Antitrust and Health Care: Current 
Antitrust Issues for the Health Care Reform (1994), and Legal and Ethical 
Controls on Biomedical Research: Seeking Consent, Avoiding 
Condescension (1993). Even prior to these formal, live symposia, the Saint 
Louis University Law Journal published a series of issues at least once and 
sometimes twice each academic year, beginning with a 1978 Health Law 
Review, that included a number of articles devoted to health law topics. 
 
 4. Tim is currently the Chester A. Myers Professor of Law at Saint Louis University and 
serves as co-director of the Center for Health Law Studies. 
 5. This year’s Symposium in some respects relates back to Tim’s joining the faculty in 
1987. In 1986, the four of us who originally created the Center of Health Law Studies on that 
napkin came to a growing recognition that the future of health law seemed likely to include 
numerous issues related to money. None of us could honestly claim significant expertise in 
financial issues related to the provision of health care. Tim applied for a faculty position to 
teach in the business associations area and, fortuitously, had spent ten years at the U.S. 
Department of Justice in Washington D.C. in its Antitrust Division as a trial attorney, and then 
as the assistant chief in charge of antitrust matters in health care. He has spent nearly twenty-
five years as an academic examining the evolution of the health care industry, and financing 
in particular, and is a vocal advocate for reforming the health care system and protecting 
consumers. 
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The first contribution to this Symposium is Professor Robert Field’s How 
the Government Created and Sustains the Private Pharmaceutical Industry.6 
Professor Field holds a joint appointment as Professor of Law at the Earle 
Mack School of Law as well as Professor of Health Management and Policy 
at the School of Public Health at Drexel University. In addition, he is a 
lecturer in healthcare management at the Wharton School of the University 
of Pennsylvania and serves as an adjunct senior fellow of the University of 
Pennsylvania’s Leonard Davis Institute of Health Economics. Professor Field 
is the author of Health Care Regulation in America: Complexity, 
Confrontation and Compromise,7 an overview of the government’s oversight 
of healthcare, and he writes a regular blog focusing on health policy for the 
Philadelphia Inquirer. He has a Ph.D. in psychology from Boston University, 
and he holds a M.P.H. from the Harvard School of Public Health, a J.D. 
from Columbia Law School, and a Bachelor’s degree from Harvard 
College. 
Professor Field takes us through the complex world of interrelationships 
of various players surrounding the development, regulation, and distribution 
of pharmaceuticals. As he notes early in his paper, “[t]he path has countless 
twists and turns. . . .” In doing so, he paints a picture of the incredible 
financial success of pharmaceutical manufacturing and the various factors 
that have contributed to it, particularly the role of research and 
development. He then proceeds to explore in great detail the role of “public 
biomedical research,” particularly the National Institutes of Health (NIH) 
and its various programs, as well as other forms of governmental support for 
the pharmaceutical industry. His discussion of the NIH includes a description 
of what it does, its history, and its phenomenal growth, and how it has 
served as an “instigator” of private drug development. Looking to its future 
role, he describes the significance of its Human Genome Project, what that 
program has already produced, and how it augurs a future of “personalized 
medicine.” NIH’s recently created National Center for Advancing 
Translation Sciences, Field observes, has the potential to create conditions 
that would allow the competitive market to bring genomic therapies to 
patients. 
Other forms of government support for the pharmaceutical industry exist 
in ways that many may not immediately identify. For example, it is clear that 
through various programs including Medicare and Medicaid, (and I would 
add, other government programs such as Tricare and the VA system) the 
government is the nation’s largest payor for pharmaceuticals. The history of 
 
 6. Robert I. Field, How the Government Created and Sustains the Pharmaceutical 
Industry, 6 ST. LOUIS U. J. HEALTH L. & POL’Y 11 (2012). 
 7. ROBERT I. FIELD, HEALTH CARE REGULATION IN AMERICA: COMPLEXITY, CONFRONTATION, 
AND COMPROMISE (2007). 
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the federal Food and Drug Administration (FDA) that has created a sense of 
trust by the American population in approved drugs and devices, also plays 
a significant role. The history of that agency’s growth as well as some of its 
problems and limitations also is traced. Various pieces of federal legislation 
apart from those relating to the programs already noted similarly have 
proven to be of significance. Thus, Field notes and describes the influence 
of the Hatch-Waxman Act in reshaping the market for generic drugs, the 
Orphan Drug Act that has led to medications for rare diseases, and 
government efforts through legislation to encourage clinical trials on the 
previously largely ignored pediatric population. Of course, federal tax policy 
and the entire patent system have both been extremely influential in 
nurturing private drug development. 
Professor Field proceeds to offer two case studies of what he describes 
as “medical miracles” to demonstrate how the various aspects of 
government support for pharmaceutical research that he described have 
operated in practice. He paints a useful picture of both the development of 
statins to reduce cholesterol levels and prevent heart attacks, strokes, and 
other cardiology related problems and the development of Taxol, the best-
selling cancer drug. 
Field concludes by arguing that we must be cognizant of the fact that 
whatever we may say about the pharmaceutical industry and its successes, 
“the greatest producer of that knowledge by far has been the United States 
government.” Without the government support he describes, the industry 
very likely would be “a shadow of its present self.” He suggests that while we 
often think of a “free-market” private sector, that market in this industry does 
not exist because the government stepped aside. Rather, its success has very 
much been a product of government involvement throughout the industry. 
The sole non-lawyer contribution to the contents of the Symposium was 
provided by Jeremy Sugarman, M.D., M.P.H., M.A., the Harvey M. 
Meyerhoff Professor of Bioethics and Medicine, professor of medicine, 
professor of Health Policy and Management, and deputy director for 
medicine of the Berman Institute of Bioethics at the Johns Hopkins 
University. Dr. Sugarman has particular expertise in the application of 
empirical methods and evidence-based standards for the evaluation and 
analysis of bioethical issues. He is the author of over 200 articles, reviews 
and book chapters. He has also edited or co-edited four books: Beyond 
Consent: Seeking Justice in Research;8 Ethics of Research with Human 
Subjects: Selected Policies and Resources;9 20 Common Problems: Ethics in 
 
 8. JEFFERY P. KAHN ET AL., BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH (1998). 
 9. JEREMY SUGARMAN, ETHICS OF RESEARCH WITH HUMAN SUBJECTS: SELECTED POLICIES AND 
RESOURCES (1998). 
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Primary Care;10 and Methods in Medical Ethics,11 and serves as an editor or 
is on the editorial board of several academic journals. 
Dr. Sugarman has served as senior policy and research analyst for the 
White House Advisory Committee on Human Radiation Experiments, 
consultant to the National Bioethics Advisory Commission, and Senior 
Advisor to the Presidential Commission for the Study of Bioethical Issues. He 
is an elected member of the American Society of Clinical Investigation and 
the Institute of Medicine, as well as a fellow of the American Association for 
the Advancement of Science, the American College of Physicians, and the 
Hastings Center. 
Dr. Sugarman’s essay, Data, Policies and Conflicts of Interest in 
Research,12 begins by noting that little has been known about the process of 
disclosure of conflicts of interest (COI): specifically, what, when, where and 
how such information should be disclosed and the results of such disclosure 
on the willingness of potential participants to agree to participate in 
research. He proceeds to describe the Conflict of Interest Notification Study 
(COINS), on which he was the senior author. 
Funded by NIH, the study reviewed COI policies and received input 
from a variety of stakeholders involved in COI, concluding that providing 
information to study coordinators about financial interests and offering 
education and training to them “would facilitate the disclosure of financial 
interests to potential research participants during the informed consent 
process.” The study developed both model disclosure language and scales 
on which trust in medical researchers could be measured. Using an internet-
based and phone-based survey and employing five different types of 
financial interest disclosures, the study concluded that the sole difference in 
trust between the five was that respondents “consistently viewed a researcher 
owning equity less favorably than a researcher receiving per capita 
payments.” The study also determined that disclosure alone was an 
inadequate method of managing such conflicts, that other tools also needed 
to be used, and that, in particular, greater attention needed to be paid to 
the issue of how per capita payments for research were determined and 
used. 
Study personnel then wanted to conduct a randomized study of the 
various empirically developed approaches to disclosing financial COI in an 
actual large scale clinical trial. Sugarman’s article proceeds to describe 
some of the challenges they successfully faced. They then identified an 
institutional review board (IRB) willing to collaborate, but none of the 
 
 10. JEREMY SUGARMAN, 20 COMMON PROBLEMS: ETHICS IN PRIMARY CARE (2000). 
 11. JEREMY SUGARMAN & DANIEL P. SULMASY, METHODS IN MEDICAL ETHICS (2d ed. 2010). 
 12. Jeremy Sugarman, Data, Policies and Conflicts of Interest in Research, 6 ST. LOUIS U. 
J. HEALTH L. & POL’Y 69 (2012). 
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industry sponsors they approached were willing to do so, citing “corporate 
fiduciary obligations,” and fears that drawing attention to the COI issue 
“was seen to be risky.” The effort then had to be abandoned. They also 
wished to conduct a study of non-financial conflicts of interest using a 
qualitative methodology, but were unable to obtain funding for it. 
Kathleen M. Boozang, the final principal presenter at the Symposium, is 
Professor of Law at Seton Hall University in New Jersey. She also serves as 
its Associate Dean for Academic Advancement and Director of its Center for 
Religiously Affiliated Nonprofit Corporations and Professor of Law. She 
previously served as Vice Provost of the University. The founder of Seton 
Hall’s health law program, she has dedicated much of her career to 
nonprofit governance issues with a special focus on religiously-sponsored 
hospitals. In the last several years, however, she has expanded her research 
and teaching to explore the legal and policy issues related to the global 
pharmaceutical and medtech industries, many of which make New Jersey 
their headquarters. 
Professor Boozang serves on the Board of Directors of the American 
Health Lawyers Association. She is a Fellow of The Hastings Center and the 
American Bar Foundation and a member of the American Law Institute and 
is a past editor-in-chief of the Journal of Law, Medicine & Ethics. She is past 
president of the American Society of Law, Medicine & Ethics and previously 
sat on the Advisory Board of the Journal of Health Law. 
Some months after the 2012 Symposium took place in St. Louis, the 
country learned of the tragedy involving the New England Compounding 
Center (NECC), a Massachusetts pharmaceutical compounding operation 
that, rather than producing tailor-made drugs for individual patients as the 
law permitted, had become a significant drug maker. Its products were 
distributed in all fifty states and it supplied even prestigious hospitals with 
tainted batches of steroids used in spinal injections. The steroids now have 
been connected to an outbreak of fungal meningitis. A recent report 
indicated that the drugs killed some 32 people, infected 400 and exposed 
approximately 14,000 people. An account of that tragedy now sits as a 
prologue to Professor Boozang’s article, Responsible Corporate Officer 
Doctrine: When is Falling Down on the Job a Crime?13 It provides an 
unusually poignant example for the thesis of the piece. 
Professor Boozang concludes the FDA’s strategic deployment of the 
Responsible Corporate Officer Doctrine (RCO) (sometimes known as the 
Park Doctrine) is quite appropriate, despite various attacks on its use. There 
are situations, she argues, that criminal responsibility should be placed on 
 
 13. Kathleen M. Boozang, Responsible Corporate Officer Doctrine: When is Falling Down 
on the Job a Crime?, 6 ST. LOUIS U. J. HEALTH L. & POL’Y 77 (2012). 
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the owners and top executives of such laboratory ventures, despite the fact 
that the government may be unable to establish criminal intent or precise 
knowledge of the conditions of the laboratories by those owners and top 
executives. Under the RCO Doctrine, the Department of Health and Human 
Services Office of the Inspector General (OIG) presumes that if there has 
been a RCO Doctrine conviction there is a presumption of federal health 
program debarment. 
In addition to focusing on fraud and abuse in the drug and device 
manufacturing sector, she notes that government agencies also have been 
focusing on both the inappropriate use and harmful effects of some of the 
industry’s products. But, as with many of the broader initiatives, she posits 
that the efforts there have largely been unsuccessful. Given that the 
government is the largest purchaser of these products in the United States, 
such unwarranted use has served to increase healthcare costs. In her article, 
Professor Boozang describes how the relationship between patent laws and 
the FDA approval process creates a variety of perverse marketing incentives. 
At the same time, laws governing company directors’ exercise of their 
fiduciary duties have failed to persuade them to assure that the companies 
strictly follow the law. The standard of review for the duty of care for 
directors and officers has come to be one of gross negligence. This, coupled 
with the business judgment rule has resulted in an extraordinarily low risk of 
liability for breaches of their fiduciary duties of care and loyalty. 
Moreover, given that the companies’ products are so critical to the 
health and welfare of individuals throughout the world, it has become 
“almost impossible to criminally prosecute life science companies because 
convictions would bar them from contracting with most nations’ 
governments, which would thereby deny their citizenry access to (potentially) 
essential medicines.” Part of the problem, Boozang notes, is that 
consequently they have become “too big to nail,” akin to the “too big to 
fail” theories posited with respect to the financial services industry a few 
years ago. 
She proceeds to review the facts of two situations in which the RCO 
Doctrine was applied:  that of Purdue Pharma’s marketing of OxyContin 
and Synthes’ marketing of bone cements used for spinal infusions. Both 
cases ultimately resulted in misdemeanor convictions and prison sentences 
for individual defendants. As a consequence, the FDA announced that it 
would increase its use of misdemeanor prosecutions against responsible 
corporate officials. These might well occur in circumstances which could 
result in debarment from participation in government health care programs 
in the face of arguments that such a result was inappropriate. The FDA 
published guidance for determining when a case would be forwarded to the 
Department of Justice for a Park Doctrine Prosecution, listing a variety of 
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factors to be considered. The OIG likewise has a guidance for when 
exclusion authority should be exercised. 
Professor Boozang concludes by suggesting that it may be possible that 
the NECC adulterated steroid situation would be an appropriate one for the 
use of the Doctrine. She addresses a number of questions about the 
propriety of its application in various situations. Noting that the Doctrine 
should be and has been used sparingly, she concludes that a suitable key to 
minimizing the inappropriate and sometimes harmful effects of life science 
companies’ behavior is for management and corporate officers to create a 
proper ethos within the company. When that does not occur, the absence of 
a finding of scienter by officers and directors ought not necessarily bar their 
criminal liability, nor consequent exclusions when it is clear that the 
environment they establish fails to meet the necessary standard. 
Marc A. Rodwin is Professor of Law at Suffolk University Law School, 
after having previously taught at Indiana, Tufts, and Brandeis Universities. 
He is the author of Conflicts of Interest and the Future of Medicine: The 
United States, France and Japan14 and Medicine, Money & Morals: 
Physicians' Conflicts of Interest.15 
Professor Rodwin has been a visiting faculty member or scholar at 
several universities in France and Japan, and has lectured on issues related 
to conflicts of interest in seven foreign countries and at more than a half 
dozen American universities. His research has been supported by the 
German Marshal Fund, and the Robert Wood Johnson Foundation among 
others, and he has held a Pew Health Policy Doctoral Fellowship as well as 
a Fulbright Commission Fellowship. 
Rodwin’s contribution to the Symposium, Independent Clinical Trials that 
Test Drugs: The Neglected Reform,16 posits that the current role played by 
drug manufacturers in the conduct of clinical trials amounts to a significant 
COI that must be remedied. This is due to the extent to which they design 
and control trials to test safety and efficacy in an effort to have the Food and 
Drug Administration (FDA) approve the marketing of the drug. He argues 
that existing “regulation . . . [has] failed to eliminate bias, flawed practice 
and fraud,” despite efforts by public officials to remedy the situation. 
Instead, as his title suggests, he argues for a new paradigm which would 
entirely eliminate pharmaceutical influence in the conduct of such trials. 
 
 14. MARC A. RODWIN, CONFLICTS OF INTEREST AND THE FUTURE OF MEDICINE: THE UNITED 
STATES, FRANCE AND JAPAN (2001). 
 15. MARC A. RODWIN, MEDICINE, MONEY & MORALS: PHYSICIANS’ CONFLICTS OF INTEREST 
(1995). 
 16. Marc A. Rodwin, Independent Clinical Trials that Test Drugs: The Neglected Reform, 6 
ST. LOUIS U. J. HEALTH L. & POL’Y 113 (2012). 
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In the introductory section, the article reviews a half dozen options 
available for the way these trials are and can be constructed on a 
continuum between maximum manufacturer control to maximum 
government control, and the extent to which each addresses COIs. He 
specifically details how each of them could be altered in an effort to 
increase control over such conflicts. He proceeds to provide a historical 
context for U.S. drug regulation, particularly in the very minimal way as it 
relates to COI. These included a variety of milestones, often precipitated by 
scandals: prohibition of marketing of dangerous or improperly labeled 
products, requirements that drugs be shown to be effective as well as safe, 
other restrictions on promotional materials, increased restrictions and 
prescriptions on how trials would be conducted including the use of phased 
testing, and requirements on how approved medications would be 
manufactured and marketing would be approved. 
Rodwin then proceeds to discuss relatively current proposals for entirely 
independent testing of drugs through the use of a new institute within NIH or 
some other government center to conduct clinical trials. He describes a 
variety of studies that have emerged demonstrating how company-funded 
studies produce publication biases and efforts by drug firms to prohibit 
researchers from publishing studies showing unfavorable results. Studies 
also document how study design, subject selection, methodology, questions 
posed, and results reported indicate further biases. He also details a variety 
of efforts both by Congress and the FDA itself between 1960 and1980 to 
improve the situation. Ultimately, the conclusion that must be reached after 
reviewing these efforts is that reform should begin with independent testing 
of new drug applications. Rodwin notes that this is the most feasible solution 
because the FDA seemingly already has the power to modify its existing 
regulations in this area. Another proposal mentioned, requiring drug firms 
to finance post-marketing studies and ordering the withdrawal of approved 
drugs for failing to do so adequately, would require an expansion of existing 
FDA authority. Similarly, the FDA has no authority to require independent 
testing of approved drugs when a sponsor designs a trial to show that a 
drug is more effective, safer, or cost-effective than competing drugs, non-
drug therapies, or an approved drug’s possible benefits for new uses. 
During the Symposium, a number of respondents provided commentary 
on the principal presentations. Efthimios Parasidis, J.D., M.B.E., Assistant 
Professor of Law at Saint Louis University, responded to Professor Field’s 
paper. Both James DuBois, Ph.D, D.Sc., the Hubert Mäder Endowed 
Professor and Director of Bander Center for Medical Business Ethics and 
The Albert Gnaegi Center for Health Care Ethics at Saint Louis University, 
and Raymond C. Tait, Ph.D., Vice President for Research at Saint Louis 
University and Professor in its Department of Neurology & Psychiatry, 
addressed Jeremy Sugarman’s talk. John Munich, J.D. a partner in the law 
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firm of Stinson Morrison Hecker LLP, who previously served as an Assistant 
United States Attorney for the District of Columbia (1991-93) and later as 
Deputy Attorney General for the State of Missouri, prosecuting healthcare 
fraud cases, replied to Kathleen Boozang’s presentation, as did Heather 
McCollum, J.D., M.H.A., P.M.P., a Manager at Polaris Management 
Partners, a consulting firm for life sciences companies. Stuart Kim, J.D., 
Senior Regulatory Counsel, Pharmaceuticals at Covidien, a medical device 
and pharmaceutical manufacturing company, and I responded to Marc 
Rodwin’s paper. 
Those who attended the Symposium learned a great deal from the 
presentations. The editors of this Journal and I trust that you will enjoy the 
additional unique contributions of the fully fleshed out papers presented 
here. 
 
 
